Pharmasset Inc (VRUS1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
303-A COLLEGE ROAD EAST PRINCETON, NJ 08540

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company has three product candidates under development, which include Clevudine, an oral, once-daily pyrimidine nucleoside analog, which is under Phase III clinical trials for the treatment of chronic HBV infection; R7128, a pro-drug of PSI-6130 in Part 3 of a Phase I clinical trial for the treatment of HCV, through a collaboration with F. Hoffmann-LaRoche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir, an oral, once-daily cytidine nucleoside analog, which has completed a Phase II clinical trial for the treatment of HIV. In addition, the company engages in the development of DFC, an oral, once-daily deoxycytidine nucleoside analog, for the treatment of HIV.

View SEC Filings from VRUS1 instead.

View recent insider trading info

Funds Holding VRUS1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VRUS1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HAHN ELLIOT F

  • Director
No longer subject to file 2012-01-12 0

INOUYE MICHAEL K

  • Director
No longer subject to file 2012-01-12 0

LEUTZINGER KURT CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2012-01-12 0

CONRAD HERBERT J

  • Director
No longer subject to file 2012-01-12 0

OTTO MICHAEL J. CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2012-01-12 0

BERREY M MICHELLE CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2012-01-12 0

WILLIAMSON ROBERT F III

  • Director
No longer subject to file 2012-01-12 0

PRICE P SCHAEFER PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2012-01-12 0

CARNEY WILLIAM J

  • Director
No longer subject to file 2012-01-12 0

ROGERS MICHAEL D. CHIEF DEVELOPMENT OFFICER

  • Officer
No longer subject to file 2012-01-12 0

BURRILL STEVEN

  • Director
0 2010-10-14 0

PRICE FREDRIC D

  • Director
30,666 2010-03-03 0

LUBETKIN PAUL EXECUTIVE VP & GENERAL COUNSEL

  • Officer
0 2009-10-14 0

QVT ASSOCIATES GP LLC

QVT FUND LP

  • 10% Owner
No longer subject to file 2009-09-22 0

SCHINAZI RAYMOND F

  • 10% Owner
No longer subject to file 2008-12-31 0

EVNIN LUKE

  • FORMER 10% OWNER
No longer subject to file 2008-06-23 0

BB BIOVENTURES L P

BAB BIO VENTURES LLP

BAB BIO VENTURES NV

MPM ASSET MANAGEMENT INVESTORS 1999 LLC

MPM BIOVENTURES PARALLEL FUND L P

MPM BIOVENTURES I LP

MPM BIO VENTURES I LLC

STEINMETZ MICHAEL

GADICKE ANSBERT

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2008-06-19 0

BB BIOVENTURES L P

BAB BIO VENTURES LLP

BAB BIO VENTURES NV

MPM ASSET MANAGEMENT INVESTORS 1999 LLC

MPM BIOVENTURES PARALLEL FUND L P

MPM BIOVENTURES I LP

MPM BIO VENTURES I LLC

EVNIN LUKE

STEINMETZ MICHAEL

GADICKE ANSBERT

  • 10% Owner
2,331,484 2008-06-17 0

GADICKE ANSBERT

  • 10% Owner
2,655,463 2008-06-13 0

SIMON NICHOLAS J III

  • 10% Owner
1,299,634 2008-04-02 0

HENNER DENNIS

  • 10% Owner
1,299,634 2008-04-02 0

MPM BIOVENTURES III QP LP

MPM BIOVENTURES III PARALLEL FUND, LP

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III LP

MPM BIOVENTURES III GP LP

MPM ASSET MANAGEMENT INVESTORS 2004 BVIII LLC

MPM BIOVENTURES III LLC

  • 10% Owner
1,325,138 2008-02-07 0

SIMON NICHOLAS J III

GALAKATOS NICHOLAS

HENNER DENNIS

WHEELER KURT

  • 10% Owner
1,325,138 2008-02-07 0

EVNIN LUKE

GADICKE ANSBERT

  • 10% Owner
1,717 2008-02-04 0

BB BIOVENTURES L P

BAB BIO VENTURES LLP

BAB BIO VENTURES NV

MPM ASSET MANAGEMENT INVESTORS 1999 LLC

MPM BIOVENTURES PARALLEL FUND L P

MPM BIOVENTURES I LP

MPM BIO VENTURES I LLC

EVNIN LUKE

STEINMETZ MICHAEL

  • 10% Owner
16,722,514 2007-05-02 0

BURRILL & CO (LIFE SCIENCES GP), LLC

BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.

BURRILL & CO (INDIANA GP), LLC

BURRILL LIFE SCIENCES CAPITAL FUND LP

  • 10% Owner
1,872,285 2007-05-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments